Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines (Q40025452)

16 September 2017

Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines (English)

1 reference

16 September 2017

1 reference

H Sasaki

1

1 reference

16 September 2017

J Hayakawa

2

1 reference

16 September 2017

Y Terai

3

1 reference

16 September 2017

M Kanemura

4

1 reference

16 September 2017

A Tanabe-Kimura

5

1 reference

16 September 2017

H Kamegai

6

1 reference

16 September 2017

H Seino-Noda

7

1 reference

16 September 2017

S Ezoe

8

1 reference

16 September 2017

I Matsumura

9

1 reference

16 September 2017

Y Kanakura

10

1 reference

16 September 2017

M Sakata

11

1 reference

16 September 2017

K Tasaka

12

1 reference

16 September 2017

M Ohmichi

13

1 reference

16 September 2017

language of work or name

English

0 references

publication date

14 January 2008

1 reference

16 September 2017

1 reference

16 September 2017

27

1 reference

16 September 2017

19

1 reference

16 September 2017

2737-2745

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210926

16 September 2017

0 references

cites work

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Involvement of estrogen receptor beta in ovarian carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogens and epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Signal transduction. A new mediator for an old hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen Inhibits Paclitaxel-Induced Apoptosis via the Phosphorylation of Apoptosis Signal-Regulating Kinase 1 in Human Ovarian Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Estrogen induction of insulin-like growth factors and myc proto-oncogene expression in the uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Cloning of the human oestrogen receptor cDNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Menopausal hormone replacement therapy and risk of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Endocrine Factors in Common Epithelial Ovarian Cancer*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Oestrogen-replacement therapy and risk of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210926

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210926

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference